Movatterモバイル変換


[0]ホーム

URL:


AU2024269222A1 - Circular rna compositions and methods - Google Patents

Circular rna compositions and methods

Info

Publication number
AU2024269222A1
AU2024269222A1AU2024269222AAU2024269222AAU2024269222A1AU 2024269222 A1AU2024269222 A1AU 2024269222A1AU 2024269222 AAU2024269222 AAU 2024269222AAU 2024269222 AAU2024269222 AAU 2024269222AAU 2024269222 A1AU2024269222 A1AU 2024269222A1
Authority
AU
Australia
Prior art keywords
rna
polynucleotides
methods
circular
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024269222A
Inventor
B. Nelson Chau
Nikolay ROZHKOV
Trent STEVENS
Rahul VUNGUTUR
Robert Alexander WESSELHOEFT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orna Therapeutics Inc
Original Assignee
Orna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orna Therapeutics IncfiledCriticalOrna Therapeutics Inc
Publication of AU2024269222A1publicationCriticalpatent/AU2024269222A1/en
Pendinglegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

Circular RNA and precursor RNA polynucleotides, along with related compositions and methods are described herein. In some embodiments, the circular RNA comprises, in the following order, a 3' self-spliced exon segment, an intervening region, and a 5' self-spliced exon segment. In some embodiments, the precursor RNA is a linear RNA comprising a 5' combined accessory element comprising a 3' permuted intron segment; an intervening region; and a 3' combined accessory element comprising a 5' permuted intron segment. In some embodiments, the circular RNA and/or precursor RNA polynucleotides comprise a coding region comprising an expression sequence. In some embodiments, the precursor RNA polynucleotide comprises a monotron. In some embodiments, the circular RNA has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, the methods and constructs result in improved circularization efficiency and/or splicing efficiency as compared to a control RNA polynucleotide comprising a native intronic sequence. Also provided herein are precursor RNA polynucleotides, circular RNA polynucleotides, and DNA polynucleotides, including polynucleotides comprising at least one modified A, C, G, or U nucleotide or nucleoside. Also presented herein are methods and compositions for the manufacture and preparation of circularized RNAs, along with methods of administering said circular RNAs and related compositions to a subject in need thereof for treatment or prevention purposes.
AU2024269222A2023-05-052024-05-03Circular rna compositions and methodsPendingAU2024269222A1 (en)

Applications Claiming Priority (5)

Application NumberPriority DateFiling DateTitle
US202363464435P2023-05-052023-05-05
US63/464,4352023-05-05
US202363470064P2023-05-312023-05-31
US63/470,0642023-05-31
PCT/US2024/027627WO2024233308A2 (en)2023-05-052024-05-03Circular rna compositions and methods

Publications (1)

Publication NumberPublication Date
AU2024269222A1true AU2024269222A1 (en)2025-10-09

Family

ID=91302109

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU2024269222APendingAU2024269222A1 (en)2023-05-052024-05-03Circular rna compositions and methods

Country Status (2)

CountryLink
AU (1)AU2024269222A1 (en)
WO (1)WO2024233308A2 (en)

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3854480A (en)1969-04-011974-12-17Alza CorpDrug-delivery system
US3832253A (en)1973-03-211974-08-27Baxter Laboratories IncMethod of making an inflatable balloon catheter
US4450150A (en)1973-05-171984-05-22Arthur D. Little, Inc.Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4667014A (en)1983-03-071987-05-19Syntex (U.S.A.) Inc.Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en)1982-12-031984-06-05Syntex (U.S.A.) Inc.Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en)1983-05-131986-02-11Societe Des Produits Nestle S.A.Food process
US4897355A (en)1985-01-071990-01-30Syntex (U.S.A.) Inc.N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
IN165717B (en)1986-08-071989-12-23Battelle Memorial Institute
US5075109A (en)1986-10-241991-12-24Southern Research InstituteMethod of potentiating an immune response
US5585481A (en)1987-09-211996-12-17Gen-Probe IncorporatedLinking reagents for nucleotide probes
FR2645866B1 (en)1989-04-171991-07-05Centre Nat Rech Scient NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
US5378825A (en)1990-07-271995-01-03Isis Pharmaceuticals, Inc.Backbone modified oligonucleotide analogs
JPH04167172A (en)1990-10-311992-06-15Nec CorpVector processor
US6319494B1 (en)1990-12-142001-11-20Cell Genesys, Inc.Chimeric chains for receptor-associated signal transduction pathways
AU669353B2 (en)1991-12-241996-06-06Isis Pharmaceuticals, Inc.Gapped 2' modified oligonucleotides
IL104570A0 (en)1992-03-181993-05-13Yeda Res & DevChimeric genes and cells transformed therewith
US5334761A (en)1992-08-281994-08-02Life Technologies, Inc.Cationic lipids
EP0760008A1 (en)1994-05-191997-03-05Dako A/SPna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
US5885613A (en)1994-09-301999-03-23The University Of British ColumbiaBilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5795587A (en)1995-01-231998-08-18University Of PittsburghStable lipid-comprising drug delivery complexes and methods for their production
US5744335A (en)1995-09-191998-04-28Mirus CorporationProcess of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
EP1027069B1 (en)1997-10-292006-07-26Genzyme CorporationGene therapy for gaucher disease
US5948902A (en)1997-11-201999-09-07South Alabama Medical Science FoundationAntisense oligonucleotides to human serine/threonine protein phosphatase genes
JP2003533437A (en)2000-02-172003-11-11ジェンザイム・コーポレイション Genetic modification of the lung as a gateway for gene delivery
FR2824431A1 (en)2001-05-032002-11-08Mitsubishi Electric Inf Tech METHOD AND DEVICE FOR RECEIVING SIGNAL
US20050222064A1 (en)2002-02-202005-10-06Sirna Therapeutics, Inc.Polycationic compositions for cellular delivery of polynucleotides
US20040014194A1 (en)2002-03-272004-01-22Schering CorporationBeta-secretase crystals and methods for preparing and using the same
ATE536418T1 (en)2004-06-072011-12-15Protiva Biotherapeutics Inc LIPID ENCAPSULATED INTERFERENCE RNA
US7745651B2 (en)2004-06-072010-06-29Protiva Biotherapeutics, Inc.Cationic lipids and methods of use
US8361794B2 (en)2004-06-292013-01-29Immunocore LimitedCells expressing a modified T cell receptor
WO2006007712A1 (en)2004-07-192006-01-26Protiva Biotherapeutics, Inc.Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
SG158175A1 (en)2004-12-272010-01-29Silence Therapeutics AgLipid complexes coated with peg and their use
CA2658768C (en)2006-07-212016-05-17Massachusetts Institute Of TechnologyEnd-modified poly(beta-amino esters) and uses thereof
CA2927045A1 (en)2006-10-032008-04-10Muthiah ManoharanLipid containing formulations
WO2008103276A2 (en)2007-02-162008-08-28Merck & Co., Inc.Compositions and methods for potentiated activity of biologicaly active molecules
JP5749494B2 (en)2008-01-022015-07-15テクミラ ファーマシューティカルズ コーポレイション Improved compositions and methods for delivery of nucleic acids
NZ588583A (en)2008-04-152012-08-31Protiva Biotherapeutics IncNovel lipid formulations for nucleic acid delivery
WO2009132131A1 (en)2008-04-222009-10-29Alnylam Pharmaceuticals, Inc.Amino lipid based improved lipid formulation
JP5147612B2 (en)2008-09-112013-02-20本田技研工業株式会社 Regulator cooling structure for motorcycles
PL2350043T3 (en)2008-10-092014-09-30Tekmira Pharmaceuticals CorpImproved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en)2008-10-232010-04-29Alnylam Pharmaceuticals, Inc.Processes for preparing lipids
CN104910025B (en)2008-11-072019-07-16麻省理工学院Alkamine lipid and its purposes
WO2010054384A1 (en)2008-11-102010-05-14Alnylam Pharmaceuticals, Inc.Lipids and compositions for the delivery of therapeutics
CN105709229B (en)2008-11-102020-07-28阿布特斯生物制药公司 Novel lipids and compositions for delivery of therapeutic agents
CA2780482A1 (en)2008-11-172010-05-10Anil K. SoodHdl particles for delivery of nucleic acids
AU2010208035B2 (en)2009-01-292016-06-23Arbutus Biopharma CorporationImproved lipid formulation for the delivery of nucleic acids
KR20210031549A (en)2009-05-052021-03-19알닐람 파마슈티칼스 인코포레이티드Lipid compositions
KR102374518B1 (en)2009-06-102022-03-16알닐람 파마슈티칼스 인코포레이티드Improved lipid formulation
CA2767127A1 (en)2009-07-012011-01-06Protiva Biotherapeutics, Inc.Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8569256B2 (en)2009-07-012013-10-29Protiva Biotherapeutics, Inc.Cationic lipids and methods for the delivery of therapeutic agents
WO2011022460A1 (en)2009-08-202011-02-24Merck Sharp & Dohme Corp.Novel cationic lipids with various head groups for oligonucleotide delivery
WO2011038160A2 (en)2009-09-232011-03-31Protiva Biotherapeutics, Inc.Compositions and methods for silencing genes expressed in cancer
EP2506879A4 (en)2009-12-012014-03-19Protiva Biotherapeutics IncSnalp formulations containing antioxidants
AU2010328336B2 (en)2009-12-072017-03-02Arbutus Biopharma CorporationCompositions for nucleic acid delivery
US9670487B2 (en)2010-01-222017-06-06Sirna Therapeutics, Inc.Cationic lipids for oligonucleotide delivery
EP2558074B1 (en)2010-04-082018-06-06The Trustees of Princeton UniversityPreparation of lipid nanoparticles
WO2011139911A2 (en)2010-04-292011-11-10Isis Pharmaceuticals, Inc.Lipid formulated single stranded rna
US10077232B2 (en)2010-05-122018-09-18Arbutus Biopharma CorporationCyclic cationic lipids and methods of use
WO2011141705A1 (en)2010-05-122011-11-17Protiva Biotherapeutics, Inc.Novel cationic lipids and methods of use thereof
JP5957646B2 (en)2010-06-042016-07-27サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
US9006417B2 (en)2010-06-302015-04-14Protiva Biotherapeutics, Inc.Non-liposomal systems for nucleic acid delivery
US20130323269A1 (en)2010-07-302013-12-05Muthiah ManoharanMethods and compositions for delivery of active agents
AU2011291582A1 (en)2010-08-202013-03-07Cerulean Pharma Inc.Conjugates, particles, compositions, and related methods
RS63329B1 (en)2010-08-312022-07-29Glaxosmithkline Biologicals SaPegylated liposomes for delivery of immunogen-encoding rna
EP3144015B1 (en)2010-09-202021-06-02Sirna Therapeutics, Inc.Low molecular weight cationic lipids for oligonucleotide delivery
WO2012044638A1 (en)2010-09-302012-04-05Merck Sharp & Dohme Corp.Low molecular weight cationic lipids for oligonucleotide delivery
CA2813024A1 (en)2010-10-212012-04-26Merck Sharp & Dohme Corp.Novel low molecular weight cationic lipids for oligonucleotide delivery
DK2663548T3 (en)2011-01-112017-07-24Alnylam Pharmaceuticals Inc PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
WO2012162210A1 (en)2011-05-262012-11-29Merck Sharp & Dohme Corp.Ring constrained cationic lipids for oligonucleotide delivery
PL2717893T3 (en)2011-06-082019-12-31Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
DK3336082T3 (en)2011-06-082020-04-27Translate Bio Inc SPLITLY LIPIDS
EP2729126B1 (en)2011-07-062020-12-23GlaxoSmithKline Biologicals SALiposomes having useful n:p ratio for delivery of rna molecules
WO2013016058A1 (en)2011-07-222013-01-31Merck Sharp & Dohme Corp.Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
HRP20190032T1 (en)2011-08-312019-02-22Glaxosmithkline Biologicals Sa PEGILATED LIPOSOMS, INTENDED FOR RNA IMPROVEMENT, CODING IMMUNOGEN
AU2012315965A1 (en)2011-09-272014-04-03Alnylam Pharmaceuticals, Inc.Di-aliphatic substituted PEGylated lipids
CA2853689C (en)2011-11-042020-06-30Nitto Denko CorporationMethod of producing lipid nanoparticles for drug delivery
WO2013073480A1 (en)2011-11-182013-05-23日油株式会社Cationic lipid having improved intracellular kinetics
US9463247B2 (en)2011-12-072016-10-11Alnylam Pharmaceuticals, Inc.Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
JP6305344B2 (en)2011-12-072018-04-04アルニラム・ファーマシューティカルズ・インコーポレーテッド Biodegradable lipids for delivery of active agents
US20140308304A1 (en)2011-12-072014-10-16Alnylam Pharmaceuticals, Inc.Lipids for the delivery of active agents
JP6182457B2 (en)2011-12-122017-08-16協和発酵キリン株式会社 Lipid nanoparticles for drug delivery systems containing cationic lipids
WO2013116126A1 (en)2012-02-012013-08-08Merck Sharp & Dohme Corp.Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
US9352042B2 (en)2012-02-242016-05-31Protiva Biotherapeutics, Inc.Trialkyl cationic lipids and methods of use thereof
EP2830594B1 (en)2012-03-272018-05-09Sirna Therapeutics, Inc.DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
HK1206645A1 (en)2012-03-292016-01-15Shire Human Genetic Therapies, Inc.Ionizable cationic lipids
ES2859923T3 (en)2013-02-282021-10-04Univ Tufts Disulfide compounds for the supply of pharmaceutical agents
EA030650B1 (en)2013-03-082018-09-28Новартис АгLipids and lipid compositions for the delivery of active agents
CA2919226C (en)2013-07-232024-05-14Protiva Biotherapeutics, Inc.Compositions and methods for delivering messenger rna
KR102096796B1 (en)2013-10-222020-05-27샤이어 휴먼 지네틱 테라피즈 인크.Lipid formulations for delivery of messenger rna
KR102095085B1 (en)2013-11-182020-03-31아크투루스 쎄라퓨틱스, 인크.ionizable cationic lipid for rna delivery
US9365610B2 (en)2013-11-182016-06-14Arcturus Therapeutics, Inc.Asymmetric ionizable cationic lipid for RNA delivery
PT3083556T (en)2013-12-192020-03-05Novartis AgLipids and lipid compositions for the delivery of active agents
EP3083579B1 (en)2013-12-192022-01-26Novartis AGLipids and lipid compositions for the delivery of active agents
US10821175B2 (en)2014-02-252020-11-03Merck Sharp & Dohme Corp.Lipid nanoparticle vaccine adjuvants and antigen delivery systems
IL289934B2 (en)2014-06-252023-04-01Acuitas Therapeutics IncNovel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3221293B1 (en)2014-11-182023-03-01Arcturus Therapeutics, Inc.Ionizable cationic lipid for rna delivery
US11669953B2 (en)2015-01-302023-06-06Hitachi High-Tech CorporationPattern matching device and computer program for pattern matching
CN107077882B (en)2015-05-042023-03-28华为技术有限公司DRAM refreshing method, device and system
PL3313829T3 (en)2015-06-292024-08-19Acuitas Therapeutics Inc.Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017034991A1 (en)2015-08-212017-03-02Pfizer Inc.Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
LT3350157T (en)2015-09-172022-02-25Modernatx, Inc. COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC SUBSTANCES
HUE061564T2 (en)2015-10-282023-07-28Acuitas Therapeutics Inc New lipids and lipid nanoparticle formulations for nucleic acid delivery
CA3007955A1 (en)2015-12-102017-06-15Modernatx, Inc.Lipid nanoparticles for delivery of therapeutic agents
WO2017117528A1 (en)2015-12-302017-07-06Acuitas Therapeutics, Inc.Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US9834510B2 (en)2015-12-302017-12-05Arcturus Therapeutics, Inc.Aromatic ionizable cationic lipid
PL3436077T3 (en)2016-03-302025-07-28Intellia Therapeutics, Inc.Lipid nanoparticle formulations for crispr/cas components
US11814627B2 (en)2016-06-202023-11-14The Board Of The Leland Stanford Junior UniversityCircular RNAs and their use in immunomodulation
US20180020547A1 (en)2016-07-132018-01-18Alcatel-Lucent Canada Inc.Underlying recessed component placement
GB201702098D0 (en)2017-02-082017-03-22Michelson Diagnostics LtdProcessing optical coherence tomography (OCT) scans
TWI650195B (en)2017-07-122019-02-11力山工業股份有限公司Miter saw with enhanced adjustable miter angle
IL275567B2 (en)2017-12-272024-03-01Takeda Pharmaceuticals CoNucleic acid-containing lipid nano-particle and use thereof
WO2019236673A1 (en)2018-06-062019-12-12Massachusetts Institute Of TechnologyCircular rna for translation in eukaryotic cells
BR112021023411A2 (en)2019-05-222022-02-01Massachusetts Inst Technology Compositions and methods of circular rna
EP4003967A4 (en)2019-07-292024-01-17Georgia Tech Research CorporationNanomaterials containing constrained lipids and uses thereof
EP4022074A4 (en)2019-08-272023-11-15The Trustees of Columbia University in the City of New York GENETICALLY ENGINEERED EXOSOMES FOR TARGETED DELIVERY
CN114430776A (en)2019-08-282022-05-03利兰·斯坦福青年大学托管委员会Modified circular RNAs and methods of use thereof
EP3920976B1 (en)2019-12-042023-07-19Orna Therapeutics, Inc.Circular rna compositions and methods
CN116034114A (en)2020-03-202023-04-28奥纳治疗公司 Circular RNA compositions and methods
JP2023525270A (en)2020-05-082023-06-15オルナ セラピューティクス インコーポレイテッド Circular RNA compositions and methods
AU2021276410A1 (en)2020-05-192023-01-19Orna Therapeutics, Inc.Circular RNA compositions and methods
WO2021263124A2 (en)2020-06-252021-12-30The Board Of Trustees Of The Leland Stanford Junior UniversityGenetic elements driving circular rna translation and methods of use
EP3945030B1 (en)2020-07-302025-05-14Hamilton Sundstrand CorporationAircraft environmental control system
AU2020469182B2 (en)2020-09-222024-07-25Huawei Digital Power Technologies Co., Ltd.Photovoltaic power generation system and method and device for detecting earth fault of photovoltaic string
CN115404240A (en)*2021-05-282022-11-29上海环码生物医药有限公司Constructs, methods for making circular RNA and uses thereof
BR112023025515A2 (en)2021-06-102024-02-27Orna Therapeutics Inc CIRCULAR RNA COMPOSITIONS AND METHODS
CA3219570A1 (en)2021-06-252022-12-29The Board Of Trustees Of The Leland Stanford Junior UniversityCompositions and methods for improved protein translation from recombinant circular rnas
CN118234867A (en)*2021-09-172024-06-21旗舰创业创新六公司Compositions and methods for producing cyclic polyribonucleotides
KR20240082384A (en)*2021-09-262024-06-10센터 포 엑설런스 인 몰레큘러 셀 사이언스, 차이니즈 아카데미 오브 사이언시스 Circular RNA and method for producing the same
US20250268828A1 (en)2021-09-302025-08-28Orna Therapeutics, Inc.Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides
TW202334080A (en)2021-11-082023-09-01美商歐納醫療公司Lipid nanoparticle compositions for delivering circular polynucleotides
EP4466029A1 (en)2022-01-212024-11-27Orna Therapeutics, Inc.Systemic administration of circular rna polynucleotides encoding muscle proteins or protein complexes
US12297285B2 (en)2022-06-242025-05-13Orna Therapeutics, Inc.Circular RNA encoding chimeric antigen receptors targeting BCMA

Also Published As

Publication numberPublication date
WO2024233308A3 (en)2025-01-16
WO2024233308A2 (en)2024-11-14
WO2024233308A9 (en)2025-04-10

Similar Documents

PublicationPublication DateTitle
US11963982B2 (en)CRISPR/RNA-guided nuclease systems and methods
LangThe mitochondrial genome of the fission yeast Schizosaccharomyces pombe: highly homologous introns are inserted at the same position of the otherwise less conserved cox1 genes in Schizosaccharomyces pombe and Aspergillus nidulans.
ES2959815T3 (en) Allele Selective Gene Editing and Uses of It
Okada et al.SINEs and LINEs share common 3′ sequences: a review
EP4289951A3 (en)Circular rna compositions and methods
WO2021226597A3 (en)Circular rna compositions and methods
Read et al.Extensive editing of both processed and preprocessed maxicircle CR6 transcripts in Trypanosoma brucei.
US6280977B1 (en)Method for generating transcriptionally active DNA fragments
CN114829598A (en)Methods and compositions for treating Usher syndrome
JPWO2021263124A5 (en)
JP2007503474A5 (en)
JP2010520757A5 (en)
US20240309368A1 (en)Targeted rna editing by leveraging endogenous adar using engineered rnas
WO1994012632A1 (en)Improvements in nucleic acid synthesis by pcr
CA3159799A1 (en)Engineering circular guide rnas
US20200263206A1 (en)Targeted integration systems and methods for the treatment of hemoglobinopathies
JP2003517283A (en) Amplification and sequencing of primer pairs and their use
WO2025102504A1 (en)Preparation method for and use of group i intron-based circular rna
AU2024269222A1 (en)Circular rna compositions and methods
CN118202045A (en) Engineered ADAR recruiting RNA and methods of use thereof
Brady et al.The human carbonic anhydrase I gene has two promoters with different tissue specificities
JP2021513871A (en) Adeno-associated virus composition for restoring F8 gene function and method of its use
JPWO2021152146A5 (en)
EA200500873A1 (en) ANTI-HIV-OLIGONUCLEOTIDE KIT AND METHOD OF THEIR APPLICATION FOR THE PREVENTION AND TREATMENT OF THE SYNDROME OF ACQUIRED IMMUNODEFICIENCY
WO2024123842A1 (en)Systems and methods for the treatment of hemoglobinopathies

[8]ページ先頭

©2009-2025 Movatter.jp